Alanyl-glutamine as Oral Rehydration & Nutrition Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2001
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
1R43DK058419-01A1
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ALGLUTAMINE, LLC
327 W MAIN ST, CHARLOTTESVILLE, VA, 22902
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RICHARD GUERRANT
() -
Business Contact:
(804) 971-6800
DZISK@AOL.COM
Research Institution:
n/a
Abstract
DESCRIPTION (Scanned from the Applicant's Abstract): This resubmission with substantially sharpened goals and experimental design based on considerable new preliminary data now fully addresses the reviewers' questions. Building on promising preliminary data, we shall define the dose effects of alanyl-glutamine relative to glutamine, glucose, and other glutamine derivatives (including acetyl-glutamine) both in vitro and in vivo. Specifically, in vitro studies will examine intestinal epithelial repair, differentiation and prevention of apoptosis. In vivo studies will examine cyclic AMP and cyclic GMP-mediated secretory diarrhea induced by the toxins of V. cholerae and ST of E. coli, respectively, and the inflammatory, destructive enteritis induced by C. difficile toxin A or cytotoxic chemotherapy. Our overall goal for this first year is to have essential in vitro and in vivo data to support pilot human studies of alanyl-glutamine's effectiveness. Success will open commercial development of an effective new ORNT product for enhancing intestinal repair and absorptive function that could have relevance across a diverse range of human and animal applications. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government